BIOMETRIC MANAGEMENT: PROTOCOL E-01
Systemic Recovery Kinetics
Systemic inhibition of the Slow-Wave Sleep (SWS) phase based on adenosine antagonist clearance and CYP1A2 gene variance.
ACTIVE SUBSTANCE AT BEDTIME
--
MILLIGRAMS IN BLOODSTREAM
SWS (Deep Sleep) Viability
--
Time of complete clearance (<25mg)
--:--
ATELIER DIRECTIVE
--